Executive Summary - Cardio AI

CARDIO AI

Executive Summary

Transforming Cardiovascular Care Through AI Innovation

Company Overview

Cardio AI is revolutionizing cardiovascular medicine through an advanced multi-agent artificial intelligence platform that provides comprehensive diagnostic support, risk assessment, and clinical decision assistance. Our innovative technology addresses the critical gap in cardiovascular care by delivering AI-powered insights that enhance clinical accuracy, improve patient outcomes, and increase healthcare system efficiency.

Founded on the principle that AI can democratize access to expert-level cardiovascular analysis, Cardio AI combines cutting-edge machine learning, deep learning algorithms, and clinical best practices to create a unified platform that serves healthcare providers from small practices to large hospital systems.

Market Opportunity

Total Addressable Market (TAM): $187 billion - Global AI in healthcare market

Serviceable Available Market (SAM): $52.4 billion - AI-powered cardiovascular diagnostics and risk assessment

Serviceable Obtainable Market (SOM): $10.3 billion - Target market over next 5 years (20% of SAM)

The cardiovascular AI market is experiencing explosive growth driven by increasing disease burden (17.9M deaths annually), healthcare system pressures, technology advancement, and the transition to value-based care. Cardio AI is positioned to capture significant market share through first-mover advantage and superior technology.

Financial Projections - Optimized Model

Cardio AI's optimized financial model demonstrates exceptional profitability with world-class 60% EBITDA margins sustained across all five years:

5-Year Total Revenue: $10.26 billion

5-Year Total EBITDA: $6.16 billion (60% margin)

Year 1 (2027): $51M revenue, $30.6M EBITDA - PROFITABLE FROM DAY 1

Year 5 (2031): $4.75B revenue, $2.85B EBITDA (60% margin)

Operating Expenses: 40% of revenue (constant) - world-class efficiency

Members: 50,000 (Y1) → 2.5 million (Y5) - 50x growth

Cumulative Cash Generated: $5.5+ billion by end of Year 5

Return on Seed Investment: 1,231x ($6.16B EBITDA / $5M seed) - no external financing needed

Our Solution

Cardio AI delivers a comprehensive, AI-powered cardiovascular healthcare platform featuring:

Multi-Agent AI System

Our platform employs three specialized AI agents coordinated by a Master Orchestrator:

Risk Assessment Agent - Five validated calculators (Framingham, ASCVD, GRACE, TIMI, CHA₂DS₂-VASc)
Diagnostic Analysis Agent - Deep learning for ECG, echo, CT, and MRI analysis
Clinical Decision Support Agent - Evidence-based recommendations following ACC/AHA guidelines

Four-Tier Pricing Model

Flexible PMPM (per member per month) pricing serving all customer segments:

Tier 1: $30 PMPM - Risk assessment with 5 validated calculators
Tier 2: $50 PMPM - AI-powered diagnostic analysis and imaging
Tier 3: $100 PMPM - Complete platform with all features
Tier 4: $40 PMPM - IoMT integration and remote patient monitoring

Blended PMPM grows from $85 (Year 1) to $190 (Year 5) as customers adopt higher tiers and complete platform.

Women's Health Module

Specialized cardiovascular risk assessment for women, addressing unique risk factors including pregnancy complications, autoimmune conditions, PCOS, and hormonal influences. Only comprehensive solution in the $2.6B women's cardiovascular health market.

Seamless Integration

EHR Integration - Compatible with Epic, Cerner, Oracle, and all major systems
IoMT Connectivity - Internet of Medical Things device integration for real-time monitoring
PACS Integration - Picture Archiving and Communication System for imaging analysis

Competitive Advantages

Only Comprehensive Platform: First solution combining risk assessment, diagnostics, and clinical decision support
Superior Economics: PMPM pricing 70% lower cost than per-study competitors while generating 60% EBITDA margins
Women's Health Leadership: Specialized module with zero direct competition in $2.6B market
Clinical Validation: Evidence-based using five validated risk calculators meeting ACC/AHA guidelines
Exceptional Profitability: 60% EBITDA margins (2x industry leaders) enable aggressive growth while maintaining superior returns
Zero Marginal Cost: Serving 2.5M patients costs same as 50K - infinite scalability
Self-Funded Growth: Profitable from Year 1, no dilution beyond $5M seed round

Key Milestones

Year 1 (2027): 50K members, $51M revenue, $30.6M EBITDA, FDA 510(k) clearance
Year 2 (2028): 250K members, $367M revenue, $220M EBITDA, major EHR partnerships
Year 3 (2029): 1M members, $1.87B revenue, $1.12B EBITDA, market leader position
Year 4 (2030): 1.75M members, $3.22B revenue, $1.93B EBITDA, international expansion begins
Year 5 (2031): 2.5M members, $4.75B revenue, $2.85B EBITDA, IPO or strategic exit

Leadership Team

Cardio AI is led by founder Sampson Kontomah with an executive team combining clinical expertise, AI/ML innovation, and healthcare business experience. CFO Everlyn Ndirangu brings financial discipline ensuring world-class operational efficiency. Todd Wiltshire (Director of Finance & Investment) and Andrew Young (Director of Investment & Government Relations) lead capital markets and investor relations. Chief Medical Advisor Dr. Tamanna Nahar ensures clinical accuracy and medical standards.

Investment Opportunity

Cardio AI represents a unique investment opportunity: a company that is profitable from Year 1, generates $6.16 billion in EBITDA over five years, requires no external financing beyond a $5M seed round, and is positioned to dominate the $187 billion AI healthcare market. The combination of world-class margins (60% EBITDA), massive market opportunity, superior technology, and exceptional team creates an investment with unprecedented risk-adjusted returns.

For investment inquiries:

Andrew Young, Director of Investment & Government Relations

[email protected]